The FAQ below is a useful guide to questions people most often ask us. However, before browsing our FAQs, we highly recommend that you read through our Product Disclosure Statement (PDS) and Target Market Determination (TMD) to fully understand the details of our products and services.
The Open Class of the Fund is no longer available for investment. Existing investors in the Open Class can continue to hold their units, but new investments into this class are not accepted.
Yes, if you’re currently an Open Class investor, you can switch to the 2-year or 3-year term classes by submitting a new Application Form along with any required identification documents. These forms are available in the Product Disclosure Statement (PDS) or on request.
The closure of the Open Class allows the Fund to better match the liquidity of the underlying portfolio with the liquidity promised to investors.
For more details about this transition or assistance with your investment, please contact Healthbridge Investments.
From its inception in December 2019 until the date of the current Product Disclosure Statement (PDS), the Fund has demonstrated consistent performance in the healthcare financing sector. Key highlights include:
For more detailed information, refer to the Performance and Financial Overview sections of the PDS or contact Healthbridge Investments directly.
*based on information available as of January 2025
When funds are received they sit in the trust account until the beginning of the following month. For example – your funds received prior to 31st January 2025 will be invested on 1st February 2025. On or around the 1st February you will receive units, expected to be at $1.0000 each and a link to establish your online account to monitor your investments. You will not receive a holdings statement nor a link to establish your online account until units are issued to you.
The fund does not currently have an income reinvestment scheme. As such all income must be paid to the investors bank account (3rd party bank accounts not permitted as per Anti-Money Laundering legislation).
Distributions are typically paid within 50 business days from the end of the calendar month. The table below provides an indicative timetable of income distribution payments for each calendar month.
Month | Paid to unit holders with units at this date (“record date”) | Indicative payment date (within 50 business days)* | Tax financial year |
January 25 | 31 January 25 | 14 April 25 | 2024/25 |
February 25 | 28 February 25 | 14 May 25 | 2024/25 |
March 25 | 31 March 25 | 14 June 25 | 2024/25 |
April 25 | 30 April 25 | 14 July 25 | 2024/25 |
May 25 | 31 May 25 | 14 August 25 | 2024/25 |
June 25 | 30 June 25 | 14 September 25 | 2025/26 |
July 25 | 31 July 25 | 14 October 25 | 2025/26 |
August 25 | 31 August 25 | 14 November 25 | 2025/26 |
September 25 | 30 September 25 | 14 December 25 | 2025/26 |
October 25 | 31 October 25 | 14 January 26 | 2025/26 |
November 25 | 30 November 25 | 14 February 26 | 2025/26 |
December 25 | 31 December 25 | 14 March 26 | 2025/26 |
*public holidays not taken into consideration so these dates are just an indication
The following information relates to current investors that remain in the “Open Class”.
The fund allows four windows in the year where it permits withdrawals from the fund, proceeds are normally paid within 50 business days from the quarter end month (see below “Relevant Date”)
Redemption Schedule after you receive 12 months of monthly income distributions.
Quarter end “Relevant Date” | Paid within 50 business days from relevant date. These dates are indicative and will vary depend upon each calendar year. | When is the redemption form required by |
25th | 14 June once March distribution NAV* is calculated and paid | 1st March |
25th June | 14 Sept once June distribution NAV is calculated and paid | 1st June |
25th September | 14 Dec once September distribution NAV is calculated and paid | 1st September |
25th December | 14 March once December distribution NAV is calculated and paid | 1st December |
*NAV – Net Asset Value is calculated monthly by Ascent Fund Services which delivers a unit price cum distribution and ex distribution. Cum distribution unit price will include the distribution before it is paid to the unitholders. Ex distribution unit price will exclude the distribution once it is paid. Unit prices will only temporarily include the distribution from the time it is calculated to the time it is paid. When all assets are operating at full capacity the unit price is expected to be $1.0000.
Unitholders should email investor services at investors@healthbridgeinvest.com.au and request a redemption form.
No. Only investors who currently hold units earn income.
It is possible. Unitholders are advised to read the risk section of the PDS and the TMD to understand the risk profile of the fund to ensure it meets an investor’s personal financial circumstance.
We encourage you to seek independent tax advice.
Since the fund is domiciled in Australian currency, we also prefer Australian bank accounts. However, investors may provide their international bank accounts. However, there are additional processing fees associated with international bank account payments. The fund will charge $AUD40 per monthly income distribution to cover the cost of processing the payment.
Investors will need to consider the effect of foreign exchange fluctuations from AUD to their local currency.
Other risks and costs may apply. International investors should invest at their own risks.
Generally, if you invest more than $500,000 or your net worth is greater than $2.5m you may be defined as a wholesale investor. You may ask for a wholesale rebate from Healthbridge Investment Management Pty Ltd of up to 0.4% (inclusive of GST) once you have received 12 months’ income distribution. This rebate will occur between the investment manager and the wholesale unitholder. This is only available for the first 12 months only.
For the 2-year and 3-year term classes, the following dates are critical:
These dates are outlined in the Key Information Summary, Applications, and Redemptions sections of the Product Disclosure Statement (PDS). For precise timelines, always refer to the PDS or contact Healthbridge Investments directly.
Units in the Closed Class are no longer available for investment, but existing Closed Class investors can switch to the 2-year or 3-year term by submitting a new Application Form.
Steps to Switch:
Once processed, your units in the 2-year or 3-year term will align with the respective term maturity and redemption policies. For further assistance, please contact Healthbridge Investments or refer to the PDS for more details.
Product Name: Healthbridge Capital
APIR Code: QFS6590AU
ISIN: AU60QFS65908
An APIR Code is a unique identifier issued by APIR® to participants and products within the Financial Services Industry.
An International Securities Identification Number (ISIN) is a 12-digit alphanumeric code that uniquely identifies a specific security. The organization that allocates ISINs in any particular country is the country’s respective National Numbering Agency (NNA).
Investors in the 2-year and 3-year terms should be aware that redemptions are generally only available at the end of the respective term’s maturity date (the Term Maturity Date). If you wish to redeem your investment, you must submit a Redemption Request at least 90 days before the Term Maturity Date. Redemption proceeds will typically be paid within 21 days after the maturity date.
Early redemptions are not typically permitted.
For exceptions, please note:
For full details, refer to the Redemption Policy outlined in the Product Disclosure Statement (PDS).
This information is issued by Healthbridge Investment Management Pty Ltd (ABN 89 631 971 081) (Corporate Authorised Representative (CAR 1277945) of Cache (RE Services) Ltd AFSL 494886) as investment manager for the Healthbridge Capital (the ‘Fund’). It contains summary information only to provide an insight into the operation and performance of the Fund. Any information or advice is general in nature. This information does not constitute advice or recommendations, and is subject to change without notice. It does not take into account the objectives, financial situation or needs of any investor which should be considered before investing. Investors should consider a copy of the Product Disclosure Statement (PDS) and Target Market Determination which is available from us, and seek their own financial advice prior to investing. The disclosure document explains how the Fund’s Net Asset Value is calculated. Returns are calculated from exit price to exit price assuming the payment of any distributions for the period as stated and represent the combined income and capital return. For a copy of our Financial Services Guide (FSG), please go to our website: www.healthbridgeinvest.com.au.
None of Healthbridge Investments, its respective officers, employees, agents, advisers or any other person named in this presentation makes any representation as to the accuracy or likelihood of fulfilment of the forward looking statements or any of the assumptions upon which they are based. To the extent permitted by law, Healthbridge Investments and its respective officers, employees, agents and advisers give no warranty, representation or guarantee as to the accuracy, completeness or reliability of the information contained in this presentation. Further, none of Healthbridge Investments or its respective officers, employees, agents and advisers accepts, to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in connection with, this presentation. Any recipient of this presentation should independently satisfy themselves as to the accuracy of all information contained herein.
This presentation is provided to you strictly on a confidential basis and the information contained herein must not be reproduced or redistributed in any format without the express written consent of Healthbridge Investments.
All financial products involve risks. You should seek independent financial advice prior to acquiring a financial product. Past performance is not a reliable guide to future performance and the capital and income of any investment may go down as well as up due to various market forces. All performance figures are confirmed by the Fund’s administrator. Healthbridge Capital was established on 3rd October 2019.
Healthbridge Investments has appointed an investment committee, whose role is to:
If you would like to invest in our product and have 100 points of certified ID ready to upload, click the button to apply online.
Note: Please download our PDS before applying
To download our Product Disclosure Statement (PDS), please complete the form below.